Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Noble Acquires Property with Significant Uranium, Rare Earth, Phosphorus & Silver Minerlaization (click to learn more) V.AFM: Record Fy2024 & Q4 ‘24 Tin Production Fy2025 Production Guidance Exploration Success (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News BioXcel Therapeutics Inc BTAI

Healthcare Biotechnology
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BTAI)

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

GlobeNewswire November 22, 2024

BioXcel Therapeutics Announces Proposed Public Offering

GlobeNewswire November 21, 2024

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

GlobeNewswire November 14, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia

GlobeNewswire November 12, 2024

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

GlobeNewswire November 8, 2024

BioXcel Therapeutics to Present at ThinkEquity Conference

GlobeNewswire October 29, 2024

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

GlobeNewswire October 15, 2024

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

GlobeNewswire September 19, 2024

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

GlobeNewswire September 5, 2024
View More News ››

Opinion & Analysis (NDAQ:BTAI)

Clinical Program Started for Agitation with Schizophrenia, Bipolar Disorder

Streetwise Reports January 6, 2020

Biopharma to Test Immunity Activator in Advanced Solid Cancers

Streetwise Reports December 19, 2019
View More Opinion ››

Bullboard Posts (NDAQ:BTAI)

BioXcel Therapeutics Announces Clinical Prioritization and U

Breaking News: $BTAI BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for...
whytestocks - September 19, 2024

BioXcel Therapeutics, Inc. (NASDAQ:BTAI): Advancing Neurosci

http://beyondspx.com/2024/07/31/bioxcel-therapeutics-inc-nasdaqbtai-advancing-neuroscience-and-immuno-oncology-pipelines-driving-igalmi...
MikeTester - August 2, 2024

Why BioXcel Therapeutics Shares Are Rising Tuesday | Benzing

BREAKING NEWS: $BTAI Why BioXcel Therapeutics Shares Are Rising Tuesday | BenzingaBioXcel Therapeutics, Inc.@(NASDAQ:BTAI) shares are...
whytestocks - February 13, 2024

BioXcel Therapeutics Announces Termination of Proposed Publi

BREAKING NEWS: $BTAI BioXcel Therapeutics Announces Termination of Proposed Public OfferingNEW HAVEN, Conn., Feb. 13, 2024 (GLOBE...
whytestocks - February 13, 2024

BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating

BREAKING NEWS: $BTAI BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term...
whytestocks - February 9, 2024

BioXcel Therapeutics Announces Completion of Patient Enrollm

Breaking News: $BTAI BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2...
whytestocks - February 6, 2024
View more Bullboard ››

Leading Edge Materials Corp.

Leading Edge Materials Corp.

Leading Edge Materials Corp. is a Canada-based company focused on developing a portfolio of critical raw material projects ...
View More »